Ancilia Bio

6 known investors

Ancilia uses CRISPR technology to engineer bacterial products with resistance to destructive viruses, enabling their use as live biotherapeutics. The company's CoVE and EPIC platforms computationally identify viromes and design bacterial therapies immune to specific viral threats.